Seems Like If Tyvaso DPI Is That Much Superior To Tyvaso, FDA Should Approve It
Not a scientist, but if Tyvaso DPI requires fewer doses for longer coverage, enables longer 6 minute walks, has been 90+% favored over Tyvaso in extended studies by clinical trial participants, etc., then why would the FDA hold it up????
People with pulmonary arterial hypertension should be clamoring for it. All JMHO.